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Summary Several oncogenes and tumour-suppressor genes have been identified that may have an important
role in the development of human breast carcinoma. Furthermore, some of these gene alterations may be
linked to the development of invasion and subsequent metastasis. Alterations in the expression of ras p21, p53
and c-erbB-2 have all been linked to tumours with rapid cellular proliferation. but the evidence that they are of
prognostic importance in patients with breast cancer is conflicting. This study explores the relationship
between expression of these oncoproteins and clinical outcome in 92 patients with either locally advanced or
metastatic breast cancer treated with prinmary endocrine therapy. Specimens of the primary carcinoma were
available for analysis of hormone receptor, Ki67 labelling index, epidermal growth factor receptor (EGFR),
c-erbB-2, p53 and ras p21. Clinical response was measured according to UICC criteria after 6 months of
treatment and all patients were followed for time to progression and overall survival. As shown previously,
oestrogen receptor (ER) negativity, high Ki67 labelling index and EGFR overexpression were associated with
a shorter time to progression and overall survival. However, no statistically significant relationship existed
between expression of ras p21, p53 or c-erbB-2 and response to treatment, time to progression or overall
survival. We conclude that staining for these three oncoproteins has no role in therapeutic decision-making in
patients with advanced breast cancer. The negative finding implies that while abnormal expression of these
genes may have an important role in the development of breast cancer, the variations in growth characteristics
of advanced breast cancer may be influenced by other factors.
Keywor: breast cancer, hormonal therapy: oestrogen receptor status: ki 67: epidermal growth factor receptor;
c-erbB-2: p53: ras p21
The development of invasive breast carcinoma involves a
multistep process which has been associated with the altered
expression of several oncogenes and tumour-suppressor genes
(Ernberg, 1990). Although present research suggests that
these abnormalities are not the primary genetic lesions, they
may be important factors in progression to invasion and
metastasis (Hall et al., 1989). Attempts to relate the altered
expression of genes such as c-erbB-2, p53 and ras p21 to the
clinical outcome of patients with stage I and II invasive
breast cancer has produced conflicting results (Slamon et al.,
1987; Ali et al., 1988; Spandidos et al., 1989). There has been
comparatively little work on the application of oncoprotein
immunostaining to patients with advanced breast cancer.
Mutation of the ras family genes is a rare event in breast
carcinogenesis. However, overexpression of the ras family
genes has been reported to occur frequently in human breast
cancer, 55-63% of clinical stage I and II tumours (Thor et
al., 1986; Spandidos et al., 1989). Overexpression of ras p21
protein is thought to arise from an alteration in the control
of expression of the normal gene sequence rather than point
mutation or amplification (Thor et al., 1986). Overexpression
of the ras family genes may represent an additional
mechanism of activation - apart from the mutations - for
these genes (Spandidos and Agnantis 1984; Watson et al.,
1990). The member of the ras genes which is particularly
overexpressed in breast tissue is unknown, since the
antibodies used to study expression of ras proteins cannot
discriminate between the three members of the ras family. A
recent report indicates that N-ras may play a significant role
in the development of breast tumours in rats (Mangues et al.,
1994). The membrane immunostaining of ras p21 together
with its biochemical activity imply that it functions as a
signal transducer and may have a major role in growth and
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differentiation ofeucaryotic cells. There is some evidence that
enhanced ras p21 expression is associated with a more agg-
ressive clinical course with lymph node involvement (Lundy
et al., 1986), but this has not been confirmed by more recent
studies (Spandidos et al., 1989).
p53 is a tumour-suppressor gene. Human p53 gene protein
is a nuclear phosphoprotein which is normally expressed at
very low levels in almost all human cells, in which it serves to
regulate cell growth and division. Alteration in the p53 gene
is the most common genetic change found in human malig-
nancies (Hollstein et al., 1991). However overexpression of
p53 does not in itself signify malignant transformation as
overexpression has also been reported in a variety of
premalignant lesions (Gusterson et al., 1991; Bennett et al.,
1992; Pignatelli et al., 1992).
Wild-type p53 protein has a short half-life. There are a
number of mutant forms of p53 protein, the majority of
which stabilise the protein, making it more easily detected
imunocytochemically. It has also been reported that there
are situations where cells can produce unusual amounts of
normal p53 protein (e.g. response to DNA damage from a
variety of causes). This can be detected immunocyto-
chemically (Hall et al., 1993; Rasbridge et al., 1993). Care
must be taken over the selection of material for immunohis-
tochemicil studies of p53 since it has been reported that the
expression of p53 protein is influenced significantly by the
method of fixation used (Fisher et al., 1994).
Positive immunostaining for p53 is seen in 27-54% of
infiltrating and in situ human breast carcinomas, but is infre-
quently found in atypical hyperplasia, indicating that it may
be significant in the early stages of breast carcinogenesis
(Bartek et al., 1990; Horak et al., 1991; Poller et al., 1992).
Many groups have shown that expression of stabilised p53
protem is associated with tumour recurrence and poor sur-
vival of patients with mammary carcinoma (Poller et al.,
1992; Thor et al., 1992; Allred et al., 1993; Barnes et al.,
1993; Goldschmitt et al., 1994).m p53 dCowb6 2 . inia i kidc.
SG Arde eta
Human c-erbB-2 encodes for a receptor-like transmem-
brane glycoprotein, p185, which has tyrosine protein kinase
activity and shares homology with the EGFR. Amplification
of the c-erbB-2 gene has been observed in 20-35% of
primary breast cancers (Spandidos et al., 1989; Zhou et al.,
1989). Initial studies suggested that amplification of the gene
was an indicator of poor prognosis in patients with positive
lymph nodes and high tumour grade (Slamon et al., 1987;
Wright et al., 1989). Overexpression of c-erbB-2 protein in
the primary tumours of patients with positive lymph nodes
has been confirmed in a number of studies to be a marker of
poor prognosis (Anbazhagan et al., 1991; Lovelin et al.,
1991; O'Reilly et al., 1991; Gullick et al., 1991; Gusterson et
al., 1992). C-erbB-2 has also been reported to be a marker of
poor prognosis in breast cancer patients with negative lymph
nodes (Gullick et al., 1991; Wmstanley et al., 1991), although
in other studies the difference did not reach statistical
significanc (Lovekin et al., 1991; O'Reilly et al., 1991;
Gusterson et al., 1992).
The role of oncoprotein immunostaining in advanced
breast cancer has received little attention. Current clinical
practice is generally dictated by the oestrogen receptor (ER)
status of the prmiary tumour, with approximately 60% of
ER-positive tumours responding to hormone treatment.
However, ER-negative tumours are not necessarily prechlded
from hormonal treatment as 10-15% will also respond to
hormones (Hawkins et al., 1987). The identification of a
better predictor of outcome would be useful in clinial man-
agement. We therefore studied the relationship between
immunostaining for ras p21, p53 and c-erbB-2 and dinical
outcome in a group of patients with advanced breast cancer
who received hormonal therapy as their first- line
treatment. As a companson, we also aseed staining of the
more established ER (Nicholson et al., 1991), progesterone
receptor (PR), the proliferative marker Ki67 (Nicholson et
al., 1991) and EGFR (Nicholson et al., 1993, 1994) in the
same patients.
Materak anI thn
Patientpopulation
Eligibility criteria for the study included first-line systemic
hormonal therapy for an index lesion, i.e. a tumour lesion
asseable for therapeutic response by the Internatonal
Union Against Cancer (UICC) criteria (Hayward et al.,
1977). There were 92 eligible patients whose age at initial
preentation with their primary tumour ranged from 25-83
with a mean of 55 years. Sixty-six (72%) of patients were
post-menopausal at the time of diagnosis of their primary
tumour.
Nine patients (9.8%) had previously received local
radiotherapy to their primary breast tumour and had pro-
gressed on this treatment before starting hormonal therapy.
The index lesions comprised both locally advanced primary
carcinoma (44.6%) and metastatic diseas (55.4%). The site
of the treated metastatic disease was 27.2% bone alone,
14.1% lung alone, 6.5% bone and lung and 7.6% visceral.
Pathological materia from the primary breast carcinoma was
available for immunohistochemical staining. All patients were
followed up to their deaths.
Measurement oftreatment response
Patients were assssed for complete response, partial res-
ponse, static disease and progression according to UICC
criteria (Hayward et al., 1977). As recome by the
British Breast Group (1974), we asessed patients for res-
ponse and static disease 6 months after commencing hor-
monal therapy. AU patients were followed up for time to
disea progression and overall survival from the time point
at which primary hormonal therapy was commenced. When
correlating response with other variabl, compkte and par-
tial responders were grouped together with static diseas as
responders. It has previously been reported that patients with
static disease on hormone therapy for 6 months have similar
survival to patients with a partial rsonse (Howell et al.,
1988; Robertson et al., 1989).
Tisu samples
Specimens consisted of either a primary tumour biopsy
before treatment or a surgially resected primary carcinoma.
Samples from all specimens were fixed in neutral buffered
formalin for 24 h and processed routinely into paraffin
blocks. Duplicate samples were immiately frozen in liquid
nitrogen and maintained at -70C. The various assays were
performed at the National Helenic Research Foundation,
Athens (ras p21), Imperial Cancer Research Fund, London
(p53) and Tenovus Institute for Cancer Research, Cardiff
(ER, EGFR, Ki67, c-erbB-2). In most tumours sequential
sections were used for measurement of these markers. When
paraffin blocks were used for immunohistochemical staining,
tissue sections 5 pm thick were mounted on slides and
deparaffiise endogenous peroxidase activity was blocked by
immersing the sections for 30 min in an aqueous solution of
3% hydrogen peroxide. AU tumours were also analysed for
histological type (Ellis et al., 1992), tumour grade (Elston
and Ellis 1991) and the presence of vascular invasion (Pinder
et al., 1994).
rasp2l
The immunohistochemical analysis was performed with
Y13259 which is a pan-ras antibody and recognises both
normal and mutant p21, regardless of whether it is the
product of H-ras, K-ras or N-ras. Immunotaining with
Y13259 was carried out as previously reported (Papadimit-
riou et al., 1988). Briefly, deparaffinised sections were washed
with phosphate-buffered saline (PBS) and treated with Y13-
259 rat monoclonal antibody (diluted 1:100) for 90min at
3rC. After washing with PBS they were treated with 1:100
biotinylated rabbit anti-rat IgG (Sigma) for 60 min at 3TC.
Streptavidin-biotin conjugated peroxidase compkx (Sigma,
1:100 in PBS) was appLied for 30 min and peroxidase activity
was visualised with diaminobenzene (Sigma). Sections were
counterstained with haematoxylin and dehydrated. ras p21
was classified as either negative, low or intense staining As
in a previous report, for analysis of rsonse, low and intense
aining were combined as positive (Papadimitriou et al.,
1988).
p53
CMI, the polyclonal antibody against p53, was used to stain
3 pm paraffin sections on poly-L-lysiecoated slides. The
CMI antibody is a rabbit high-titre polyclonal antserum
raised against human recombinant wild-type p53 protein.
CMI antibody recognises both wild-type and mutant forms
of the protein (Midgeley et al., 1992). Briefly we used a
peroxidase conjugated streptavidin-biotin technique without
antien retrieved. The peroxidase reaction was demonstrated
with diaminobenzene as chromogen with metal t
of the final colour reaction. Sections were counterstained
with fast red (Bares et al., 1993). p53 staining was assessed
by two idependent observers according to the percentage of
cells staining and the overall intensity of the cells staining.
Intensity was graded as negative (0) (no evidence of any
positive staining in tumour cells), low (1) (weak staining in
tumour cells only visible under the high power of the micro-
scope), moderate (2) (positive staining of tumour cells evident
under the low power of the microscope) and intense (3)
(strong positive staining seen under the low power of the
microscope). Proportional staining was claified as negative
(0); <25% (1), 25-50% (2), 50-75% (3) and >75% (4). An
overall value for p53 was then obtaied as the product of
intensity and percentage staining ranging from 0 to 12.
Negative staining was taken as a p53 product of <1 and all
other values as positive for exploring the clinical correla-
tions.
1260C-erbB-2
The PAbl antibody to c-erbB-2 p185 (Triton Bioscience) was
used according to the manufacturer's instructions. Staining
was classified as positive ifany ofthe tumour cell membranes
stained with this antibody.
EGFR
EGFR-1, a mouse monoclonal anti-EGFR antibody (Amer-
sham Ltd, Amersham, UK) was used to determine the exp-
ression of EGFR as previously reported (Nicholson et al.,
1994) on froz section samples. In this publication we
assessed EGFR as a predictor ofendocrine response in breast
cancer and established cut-off klvels for the percentage of
cells which stain positive. In the present report a negative
result was considered when <20% of cells stained, mild
when 20-60% stained and strongly positive when >60%
cells stained. For analysis of clinical outcome, low and
intense staining were combined as positive.
Hormone receptor status
The presece of ER was determined using Abbott ER-ICA
monoclonal kit (Abbott Laboratories, North Chicago, USA),
as previously described (Walker et al., 1988; Robertson et al.,
1992). Briefly the ER-ICA employs rat anti-human ER
antibody, H222. This antibody was incubated with a 5pm
frozen section of breast tumour and after washing was fol-
lowed by a bridging antibody (goat anti-rat IgG) and finally
a rat peroxidase-anti-peroxidase complex. Peroxidase
activity was dete by the incubation ofthe antibody com-
plex with diaminob n and hydrogen peroxide. Tumours
were clasified as ER negative by the ER-ICA if <5% of
tumours cells stained positive.
The presence ofPR was determined in the same manner as
ER this time usng Abbott PgR-ICA monoclonal kit (Abbott
Laboratories). Tumours were cassified as PR negative if
<5% of tumour cells stained positive.
Kk67 labelling idex
The antibody Ki67 recognises an antigen revealed in cell
cycle. Frozen sections were air dried, fixed in acetone for
10 mm and staied by the Ki67 monoclonal antibody (Dako
Laboratories, Glostru, Denmark) at a dilution of 1:15,
followed by peroxidase-conjugated rablit anti-mouse
immunoglobulins at a dilution of 1:50. The peroxidase was
m p53ado_wbS-2,in.-brow
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demonsate using hydrogen peroxide and diaminobenzen
with imiazole e to give a brown nuclear stain-
ing. Sections were counterstained with haematoxylin. Stain-
ing was recorded as percentage ofpositive tumour cell nuclei;
0-10% was considered neative, 11-29% mildly positive
and 30% or more strongly positive. For analysis of crlna
outcome, low and intense staining were combined as
positwe.
Statistics
Correlations between pathological and immunohistochemical
variables and clinial resonse was examined using chi-square
analysis or Fisher's exact test where apriate. Plots of
time to progression and overall survival were made using the
method of Kaplan-Meier and univanate analysis of
differences between groups carried out with the log-rankl test.
Multivariate analysis of variables affecting time to progres-
sion and overall survival were examined using a Cox regres-
sion model in a forward stepwise manner. A statistically
significant difference was observed when P<0.05.
Resels
Twuour biology
In 41 (44.6%) of patients the index lesion was the primary
breast tumour itself. The majority of patients had ductal
carcinoma ofno specific type (57.6%) and 20.6% had lobular
carcinoma. Vascular invasion was definitely seen in 28.3% of
patients. The majority of primary carcnomas were either
grade 2 (42.4%) or grade 3 (54.3%).
Fify-five patients (59.8%) were ER positive while PR
positivity was seen in 41.3% ofpatients. A total of 85.9% of
tumours were Ki67 positive and 60.9% were EGFR positive.
The tumours of 66 patients (71.8%) stained positive for ras
p21. Only 24 patients (26.1%) had tumours which stained
positive for c-erbB-2. Overall, 39 patients (58%) had tumours
which stained positive for p53.
Response to hormonal therapy
First-line hormonal therapy was tamoxifen in 64 patients
(69.6%), Zoladex in six (6.5%), Zoladex plus tamoxifen in 19
(20.7%) and megesterol acetate in three (3.3%). Asessment
by UICC criteria at 6 months showed complete response was
seen in 11 (12%), partial in eight (8.7%) and static disease in
Table I Immunohistochemical parameters and clinial resPonse
Variable
Grade
Vascular invasion
ER status
PR status
Ki67 status
EGFR status
c-erbB-2 status
p53 status
ras p21 status
Category
2
3
No
Yes
Unknown
Neptive
Positive
Negtive
Positive
Negatve
Positive
Negative
Positive
Negative
Positive
Negative
Positive
Negative
Positive
Resos (36)
2
22
12
24
9
3
3
33
15
21
13
23
26
10
29
7
15
21
8
28
Progremion (56)
17
38
35
17
4
34
22
38
17
0
56
10
46
39
17
24
32
18
38
1261
P-value
0.005
0.85
<0.001
0.02
<0.001
<0.001
0.24
0.91
0.30m4 p53 ami c-wi B-2 in-m mlh,uCm Po SG Ardw et alF
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17 (18.5%). Within 6 months from initiation of therapy, 56
patients (61%) had progressed on hormonal therapy. The
median tim to progression following hormonal therapy was
5.0 months (range 1-86 months). At last follow-up, 80
patients (87%) had eventually progressed on hormonal
therapy. Overall survival was a median of 25 months from
commencig hormonal therapy with a range of 1-86
months. 76 patients (83%) had died at last follow-up.
Relationship between unmunohistochemical staing and
clinical response
Table I illustrates these relationships. There were 36 res-
ponders and 56 progressors at the 6 month assessment. The
group of responders was significantly older and more likely
to be post-menopausal than the progressors (mean age 60 vs
52; P =0.002). In addition, a clinical response was more
likely to be observed in locally advanced tumours than in
patients whose index lesion was a distant metastatic site.
There were significntly more grade 3 carcinomas in the
progressors (P= 0.005), but lymphovascular invasion was
not a predictor of progression.
As expected, ER negativity, PR negativity, a high Ki67
labelling index and positive EGFR staining all correlated
with progression of disease on hormonal therapy. Total p53,
ras p21 and c-erbB-2 staining did not correlate significantly
with response to hormonal therapy. When the complete,
partil and static diease was considered separately, there was
no significant correlation with either the degree of ras p21
staining (P = 0.84) or with total p53 expression (P = 0.52).
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1:Relationship between clinicopathological variables and rasp21
expression
Of the 92 patients, 66 (71.8%) were positive for staining for
the ras p21 product. There was no significant relationship
between tumour grade, ER status, PR status, Ki67, EGFR
or c-erbB-2. There was a significant relationship between
both the intensity of p53 staining (P = 0.006) and the per
cent staining (P = 0.01), but this significance showed only a
trend when the p53 product was calculated and compared
with ras p21 staining (P= 0.06).
Relationship between clinicopathological variables andp53
expression
Of the 92 patients, 53 (57.6%) were positive for p53. There
was a trend for p53-positive tumours to be high grade
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(P = 0.08), have lymphovascular invasion (P = 0.05) and be
ER positive (P= 0.06) and to stain ras p21 positive
(P = 0.06). However, there was no relationship demonstrated
for Ki67, EGFR or c-erbB-2.
Relationship between clinicopathological variables and c-erbB-2
expression
There was no correlation between c-erbB-2 and ras p21
status, p53 status or response to endocrine therapy.
Time to progression and overall survival
Figures 1 and 2 demonstrate the Kaplan-Meier plots for
tine to progression and overall survival for the different
immunohistochemical parameters. On univariate analysis, ER
c-erbB-2 status
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Fuwe 2 Kaplan-Meier plots for overall survival from commencement of hormonal treatment according to ER status, Ki67 index
labelling, EGFR, c-erbB-2, p53 and ras p21 staining (0, positive; *, negative). Univariate comparisons have been made with the
log-rank- test.
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negativity, Ki67 positivity and EGFR positivity were highly
significnt for both a shorter time to progression and a poor
overall survival (P<0.001). However, the staining of the
orginal primary tumour for c-erbB-2, p53 and ras p21 did
not correlate significantly with time to progression and
overall survival.
All relevant factors were examined for their influence on
time to progression and overall survival using the Cox regres-
sion model. ER status (P<0.001), Ki67 (P = 0.006) and
EGFR (P = 0.004) were the only factors found to be statis-
tically significant independent predictors of time to progres-
sion. For overall survival, only ER status (P= 0.008) and
Ki67 labelling index (P=0.003) were independent co-
variates.
The aim of the study was an attempt to identify one or more
oncoproteins whose expression may serve as a guide to
therapy as well as a prognostic indicator in advanced breast
cancer. Examination of ras p21, p53 and c-erbB-2 showed no
correlation with either clinical response, time to progression
or overall survival from the date on which hormone treat-
ment was started.
The validity of the series is confirmed by the observation
that the clinical outcome variables were highly related to ER
status, Ki67 and EGF receptor status. In primary breast
carcinomas ER status is a measure of endocrine respon-
siveness (Hawkins et al., 1987; Low et al., 1992) while Ki67
and EGFRs are related to the proliferative rate of the
primary tumour (Sainsbury et al., 1987; Locker et al., 1992).
Our data imply that the tumour retains its same biological
characteristics in the locally advanced and metastatic
phases.
The finding that there was no significant correlation
between ras p21 expression and either tumour histology or
the other immunohistochenical parameters is of interest in
light of previous research. Work by Ohuchi et al. (1986) and
Going et al. (1992) indicates that ras p21 expression increases
through the histological progression from normal breast
epithelium to in situ cancer. There is little further inacrease in
invasive cancer and metastases have a rather heterogeneous
staining, implying that the expression of ras p21 is not
required for maintenance of the transformed phenotype
(Fromowitz et al., 1987). There was early evidence that
enhanced ras p21 expression was associated with rapidly
proliferating, high-grade tumours with lymph node metas-
tases, but others have failed to show any relationship with
histological type, tumour grade, hormone receptor status,
tumour diameter, lymph node status or vascular invasion
(Lundy et al., 1986; Spandidos et al., 1989). In conjunction
with the present study in advanced breast cancer, there is
little support for that premise that ras p21 expression is
associated with aggressive tumour behaviour.
In a previous study by our group of stage I and II breast
cancers expression of stabiised p53 protein correlated
significantly with markers of poor prognosis - i.e. high
tumour grade, expression of EGFR and c-erbB-2 protein
overexpression (Poler et al., 1992). In the present series,
there was a trend to such an association with grade and
vascular invasion, but not with either the EGFR or c-erbB-2.
In our previous study (Poller et al., 1992) p53 expression
showed only a weak link with patient survival. Other studies
have reported a stronger correlation between p53 expression
and poor prognosis (Thor et al., 1992; Allred et al., 1993;
Banes et al., 1993; Goklschmid et al., 1994) and even that it
is independently significant on multivariate analysis (Thor et
al., 1992).
In our previous study of stage I and H disease (Poller et
al., 1992) we reported a strong inverse relationship of p53
expression with ER status. In the present study there was a
non-signint trend for ER-positive tumours to be p53
positive. One possible explanation for this difference between
our two studies may be that the present study involves a
maller, more selct group of patients who have ilentified
their poorer prognosis by presenting with a locally advanced
primary cancer or by developing symptomatic metastases. In
these particular tumours ER positivity is not associated with
as good a prognosis as ER positivity in stage I and H
tumours, some of which will never recur. It may not be too
surprising therefore that the tumours in the present study
express p53 and ER together.
It is difficult to interpret the trend for p53-positive tumours
to be ras p21 positive as well, in view ofthe fact that ras p21
does not correlate with any of the other parameters
associated with rapid cellular proliferation. One explanation
may be that in previous series there was a much larger
proportion of patients with grade 1 tumours, while in this
study the vast majority were grade 2 or 3. This clustering of
grades may have reduced the magnitude of the differences
previously observed.
C-erbB-2 did not correlate with either ras p21 or p53
oncoprotein expression. In this same series of patients we
have previously reported that c-erbB-2 does not correlate
with EGFR or Ki67 (Nicholson et al., 1993). In vitro studies
have shown that in ER-positive breast cancer cell lines the
expression of c-erbB-2 is oestradiol regulated. Oestradiol
stimulated cell proliferation while at the same time it down-
regulated the expression of c-erbB-2 in ER-positive cell ines
MCF-7 and T47D (Dati et al., 1990) and MCF-7 and ZR-
75.1 (Russell and Hung, 1992). Further studies by the first of
these two groups reported that the anti-oestrogen tamoxifen
inhibited cell growth and enhanced c-erbB-2 expression in
ER-positive cell lines T47D and ZR75.1. Tamoxifen had no
effect on cell growth or c-erbB-2 expression in the ER-
negative cell line MDA.MB231 (Antoniotti et al., 1992). The
other group has shown that while oestradiol had no effect on
the growth ofc-erbB-2 expression of the ER-negative cell line
BT474, the addition of ER to the cell line BT-474 was
sufficient to allow oestradiol to repress the expression of
c-erbB-2 (Russell and Hung, 1992). It is therefore intesting
that in the present study expression of c-erbB-2 by the
primary tumour did not correlate with response to endocrine
therapy.
c-erbB-2 expression did not correlate with patient survival.
This is contrary to a previous publication looking at a similar
number but different group of patients with advanced breast
cancer in which we reported that c-erbB-2 expression did
correlate with survival (Lovekin et al., 1991). It is unckar
from the apparently confliing resuts of our two studies
whether c-erbB-2 expression does correlate with survival in
patients with advanced breast cancer.
In conclusion, immunostaining ofthe primary tumour with
monoclonal antibodies to ras p21, c-erbB-2 and p53 either
separately or as a panel of stains did not in this study
provide a useful predictor of response to hormonal therapy
in locally advanced or metastatic breast caer. Furthermore,
these parameters bore no relationship to either the time to
progression or the overall survival from the time of ins-
tituting hormonal therapy. These finings, particully for
c-erbB-2, do not appear to be in keeping with in vitro data
suggesting c-erbB-2 expression may be hormonally regulated,
at least in ER-positive breast cancer cell lines. It would be
interesting to note the effect oftamoxifen on c-erbB-2 expres-
sion of tumours by sequential biopsies. This is currently the
subject of ongoing studies.
We are grateful to Tenovus Institute, Cardiff, for their financial
support, which funded some of the laboratory data.
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